Salt Lake City

Utah GOP's Youth Gender Care Crackdown Rockets Through Capitol

AI Assisted Icon
Published on February 19, 2026
Utah GOP's Youth Gender Care Crackdown Rockets Through CapitolSource: LoneStarMike, CC BY-SA 3.0, via Wikimedia Commons

Utah lawmakers are moving quickly on a bill that would effectively end most gender-affirming hormonal care for minors, with the measure clearing the House and now landing in a key Senate committee. The proposal would sharply restrict doctors from prescribing puberty blockers and cross-sex hormones to most youth. Backers say they are protecting kids from irreversible decisions, while opponents warn it will rip away what they describe as lifesaving care for some of the state's most vulnerable young people.

What HB174 would do

HB174, officially titled the "Sex Characteristic Change Treatment Amendments," targets hormonal treatment for transgender minors. It would make it unlawful for health care providers to prescribe cross-sex hormones or puberty blockers to minors, except in narrow grandfathered situations. Only patients who were diagnosed with gender dysphoria before Jan. 28, 2023, could continue receiving treatment, and only until Jan. 28, 2027. The law is set to take effect May 6, 2026, and violations would be treated as unprofessional conduct under state law, according to the bill text on the Utah Legislature.

Where it stands in the Legislature

The House signed off on HB174 on Feb. 5, 2026, then sent it across the chamber. The bill has been referred to the Senate Judiciary, Law Enforcement and Criminal Justice Committee for its next hurdle, according to LegiScan. That committee review comes before any full Senate vote, and current tracking shows hearings are being lined up for this session.

How lawmakers and advocates reacted

Before the House vote, lawmakers sat through hours of emotional testimony. Detransitioner Chloe Cole and several medical professionals argued that puberty blockers and hormones carry uncertain long-term risks and should not be given to minors. On the other side, parents, health care providers and LGBTQ advocates pleaded with legislators not to move forward, warning the bill would harm transgender youth and misinterpret the available science. The House health committee had already advanced the measure after heated public comment and detailed presentations from both supporters and critics, as reported by KSL.

Advocates push back

LGBTQ advocacy group Project Rainbow Utah blasted the committee outcome as "deeply troubled" and called on Gov. Spencer Cox to veto the bill. The group pointed to the state's own commissioned review, which it says found benefits to gender-affirming care for young people. In its statement, the organization argued that "GAC is life-saving medicine" and urged the governor to "stand up for the rights and dignity of trans Utahns," according to comments shared with FOX13 News Utah.

Legal implications

Under the bill, any provider who offers hormonal transgender treatment to a minor after the cutoff could be found guilty of unprofessional conduct, a label that can trigger discipline from state licensing boards. HB174 also strips out the existing section of law that had ordered lawmakers to conduct an ongoing systematic review of medical evidence on this issue, language spelled out in the enacted bill text on the Utah Legislature.

What's next

For now, HB174 sits in the Senate committee, where it faces more hearings, potential amendments and a committee vote. If it clears that stage, the bill would move to the full Senate, then back to the House if any changes are made, before landing on Gov. Cox's desk for either a signature or a veto. Lawmakers from both parties say they expect additional evidence and expert testimony to play into how the final version looks, according to LegiScan.

The fight in Utah is part of a wider, highly charged national battle over access to gender-affirming care for minors. Families, clinicians and advocates in the state say the stakes are high: depending on how HB174 ultimately lands, some young people may have to cross state lines to continue treatment or give it up entirely, while lawmakers continue to wrestle with competing studies, emotional testimony and sharply divided public opinion.